Commodore Capital has fully exited its stake in Viridian Therapeutics, divesting 3.2 million shares valued at approximately $69 million on February 17, 2026. The move reduces the fund's holding from 3.4% of total assets to zero, marking a complete departure from the clinical-stage biopharmaceutical company despite significant recent performance gains.
Viridian's stock has appreciated 75% over the past twelve months, a period that included substantial momentum heading into 2026. The year ahead presents multiple catalysts for the company, including anticipated FDA approval decisions and Phase 3 clinical trial data releases that typically influence investor positioning in the biotech sector.
The timing of Commodore Capital's exit suggests a strategic reallocation of capital, though the fund's rationale for the divestment remains undisclosed. Large institutional exits from appreciating biotech positions often reflect portfolio rebalancing or shifting conviction on clinical or commercial prospects, though such moves do not necessarily indicate negative assessments of near-term catalyst timelines.